1194 related articles for article (PubMed ID: 16730485)
1. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
2. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
3. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
4. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
Jick SS; Jick H
Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
[TBL] [Abstract][Full Text] [Related]
5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
7. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
8. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
Lidegaard O
Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Cole JA; Norman H; Doherty M; Walker AM
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
[TBL] [Abstract][Full Text] [Related]
11. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
12. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
13. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
Burnhill MS
Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
[TBL] [Abstract][Full Text] [Related]
14. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
15. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
16. The truth about oral contraceptives and venous thromboembolism.
Shulman LP; Goldzieher JW
J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
[TBL] [Abstract][Full Text] [Related]
17. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and venous thromboembolism: an epidemiological review.
Lidegaard O
Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
Jick SS; Hagberg KW; Hernandez RK; Kaye JA
Contraception; 2010 Jan; 81(1):16-21. PubMed ID: 20004268
[TBL] [Abstract][Full Text] [Related]
20. A perspective on the concept of "risk".
Westhoff CL
Dialogues Contracept; 1996; 5(1):8-9. PubMed ID: 12347723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
